Avoro Capital Advisor LLC recently announced the acquisition of new stake in Apellis Pharmaceuticals Inc. (NASDAQ:APLS). The institutional investor has increased its shareholding in the Healthcare company by 4.94% to 10.62 million shares with purchase of 0.5 million shares. This fresh investment now brings its stake to 9.28% valued currently at $886.44 million. In addition, The Vanguard Group, Inc. raised its holdings by 0.18 million to 8.96 million shares. And T. Rowe Price Investment Manageme has lifted its position by 5.92% or 0.33 million shares – to 5.84 million shares.
With over 1.51 million Apellis Pharmaceuticals Inc. (APLS) shares trading Tuesday and a closing price of $86.09 on the day, the dollar volume was approximately $129.83 million. The shares have shown a positive half year performance of 70.64% and its price on 05/23/23 lost nearly -1.59%. Currently, there are 113.87M common shares owned by the public and among those 93.52M shares have been available to trade.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Insiders at the company have transacted a total of 222 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 94 of these insider trades were purchases, accounting for 2,343,443 shares. Insider sales of the common stock occurred on 128 occasions, with total insider shares sold totaling 1,632,125 shares.
The top 3 mutual fund holders in Apellis Pharmaceuticals Inc. are Vanguard Health Care Fund, Vanguard Total Stock Market ETF, and Vanguard Small Cap Index Fund. Vanguard Health Care Fund owns 3.22 million shares of the company’s stock, all valued at over $268.89 million. Vanguard Total Stock Market ETF bought 0.13 million shares to see its total holdings expand to 3.02 million shares valued at over $251.94 million and representing 2.64% of the shares outstanding. Vanguard Small Cap Index Fund bought 96287.0 shares to bring its total holdings to over 2.55 million shares at a value of $212.42 million. Vanguard Small Cap Index Fund now owns shares totaling to 2.22% of the shares outstanding.
Shares of Apellis Pharmaceuticals Inc. (NASDAQ: APLS) opened at $87.26, down -$0.22 from a prior closing price of $87.48. However, the script later moved the day high at 88.14, down -1.59%. The company’s stock has a 5-day price change of -1.81% and 30.80% over the past three months. APLS shares are trading 66.49% year to date (YTD), with the 12-month market performance up to 92.12% higher. It has a 12-month low price of $37.66 and touched a high of $94.45 over the same period. APLS has an average intraday trading volume of 1.81 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.30%, 9.80%, and 38.56% respectively.
Institutional ownership of Apellis Pharmaceuticals Inc. (NASDAQ: APLS) shares accounts for 89.80% of the company’s 113.87M shares outstanding. Mutual fund holders own 42.85%, while other institutional holders and individual stakeholders account for 45.82% and 30.90% respectively.
It has a market capitalization of $9.87B and a beta (3y monthly) value of 1.24. The earnings-per-share (ttm) stands at -$6.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.73% over the week and 3.97% over the month.
Analysts forecast that Apellis Pharmaceuticals Inc. (APLS) will achieve an EPS of -$1.37 for the current quarter, -$1.33 for the next quarter and -$3.03 for 2024. The lowest estimate earnings-per-share for the quarter is -$1.57 while analysts give the company a high EPS estimate of -$0.84. Comparatively, EPS for the current quarter was -$1.46 a year ago. Earnings per share for the fiscal year are expected to increase by 30.50%, and 44.50% over the next financial year. EPS should grow at an annualized rate of 33.30% over the next five years, compared to -42.80% over the past 5-year period.
Leave a Reply